Cargando…

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messina, Carlo, Cattrini, Carlo, Soldato, Davide, Vallome, Giacomo, Caffo, Orazio, Castro, Elena, Olmos, David, Boccardo, Francesco, Zanardi, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492871/ https://www.ncbi.nlm.nih.gov/pubmed/32963528 http://dx.doi.org/10.1155/2020/4986365

Ejemplares similares

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone
por: Zanardi, Elisa, et al.
Publicado: (2019)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
por: Cavo, Alessia, et al.
Publicado: (2018)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review
por: Caffo, Orazio, et al.
Publicado: (2021)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2021)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
por: Capaia, Matteo, et al.
Publicado: (2018)

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients
por: Cattrini, Carlo, et al.
Publicado: (2023)

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
por: Lozano, Rebeca, et al.
Publicado: (2020)

Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?
por: Barranco, Rosario, et al.
Publicado: (2020)

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
por: Shah, Sidrah, et al.
Publicado: (2021)

BRCA2 and Other DDR Genes in Prostate Cancer
por: Nombela, Paz, et al.
Publicado: (2019)

Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
por: Caffo, Orazio, et al.
Publicado: (2018)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
por: Merz, Valeria, et al.
Publicado: (2020)

Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa)
por: Nuzzo, Pier Vitale, et al.
Publicado: (2015)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

Onset of vitiligo following targeted therapy for BRAF(V600E)-mutated melanoma: case report
por: Brugnara, Sonia, et al.
Publicado: (2019)

Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation
por: Brugnara, Sonia, et al.
Publicado: (2018)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients
por: Arecco, Luca, et al.
Publicado: (2020)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
por: Rauch, Simon, et al.
Publicado: (2016)

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death
por: Nuzzo, Pier Vitale, et al.
Publicado: (2012)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
por: Boussios, Stergios, et al.
Publicado: (2022)

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation
por: Han, Hyunho, et al.
Publicado: (2022)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

Splice Variants of Androgen Receptor and Prostate Cancer
por: Caffo, Orazio, et al.
Publicado: (2016)

Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
por: Ponder, B
Publicado: (2000)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers
por: Tommasi, Chiara, et al.
Publicado: (2021)

Scar-Free Laparoscopy in BRCA-Mutated Women
por: Restaino, Stefano, et al.
Publicado: (2022)

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival
por: Biglia, Nicoletta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rmpqo1s4nv4ep2a148oncq342q